Our Pipeline

Arcellx is developing ARC-sparX platform candidates in a range of disease areas. The pipeline is designed for efficient, stepwise development of the ARC-sparX platform.

Multiple Myeloma

CandidateCan
DiscoveryDisc
PreclinicalPre
Phase 1P1
Phase 2P2
Phase 3P3
CART-ddBCMA
CART-ddBCMA

CART-ddBCMA is a cell therapy candidate involving patient-derived, or autologous, T cells that have been genetically modified to recognize and kill specific cells expressing BCMA, a target antigen for multiple myeloma. This candidate utilizes a chimeric transmembrane protein for antigen recognition that includes a novel proprietary binding domain in place of the traditional scFv binding domain of conventional cell therapies. The domain has been engineered to reduce immunogenicity. Arcellx’s CART-ddBCMA Phase 1 trial for the treatment of relapsed and refractory multiple myeloma has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration.

ACLX-001
ACLX-001

ACLX-001 is in development for the treatment of multiple myeloma. ACLX-001 is composed of ARC-T cells and a bivalent sparX protein targeting BCMA. This sparX-BCMA protein utilizes the same antigen binding domain as the Arcellx CART-ddBCMA.

Discovery

Arcellx is exploring additional targets for the treatment of MM.

AML/MDS

CandidateCan
DiscoveryDisc
PreclinicalPre
Phase 1P1
Phase 2P2
Phase 3P3
ACLX-002
ACLX-002

ACLX-002 is an ARC-sparX platform cell therapy using a sparX protein targeting CD123 for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

Discovery
Discovery

Arcellx is exploring additional targets for the treatment of AML/MDS.

Solid Tumors

CandidateCan
DiscoveryDisc
PreclinicalPre
Phase 1P1
Phase 2P2
Phase 3P3
Discovery
Discovery

Arcellx has engineered novel sparX proteins for three distinct solid tumor-associated antigens and plans to select a lead candidate in preparation for clinical testing in a solid tumor indication.

Autoimmune Diseases

CandidateCan
DiscoveryDisc
PreclinicalPre
Phase 1P1
Phase 2P2
Phase 3P3
ACLX-001
ACLX-001

ACLX-001 is composed of ARC-T cells and a bivalent sparX protein targeting BCMA. ACLX-001 is the first candidate cell therapy for the treatment of autoimmune diseases, representing an expansion beyond oncology.

Discovery
Discovery

Arcellx is exploring additional targets for the treatment of autoimmune diseases.